Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 2 Squamous Intraepithelial Lesions 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Adenocarcinoma Locally Advanced 1 Neoplasm Metastasis 1 Melanoma 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 HIV Seropositivity 1 Gynecological Cancers 1 Colorectal Neoplasms 1 Colorectal Liver Metastases 1 Carcinoma, Hepatocellular 1

Interventions

aldesleukin 22 Sunitinib 21 Bevacizumab 16 Interleukin-2 14 Everolimus 14 Interferon-alpha 13 Gemcitabine 13 Cyclophosphamide 13 fludarabine phosphate 11 Peripheral Blood Stem Cell Transplantation 9 Sorafenib 8 Filgrastim 8 Axitinib 8 Nivolumab 7 pembrolizumab 6 Ipilimumab 6 Doxorubicin 6 Carboplatin 6 sargramostim 5 cabozantinib 5 Capecitabine 5 Thalidomide 4 Tacrolimus 4 Radiotherapy 4 Radiosurgery 4 Neoadjuvant Therapy 4 Mycophenolic Acid 4 Magnetic Resonance Spectroscopy 4 Erlotinib Hydrochloride 4 Chemotherapy, Adjuvant 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Kidney Neoplasms × Electroporation × Clear all

NCT02828709 2016-09-27

Safety and Feasibility of IRE for SRMs

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Unknown

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡